Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?

References (11)

1. Leung C. Clinical Features of Deaths in the Novel Coronavirus Epi-demic in China. Rev Med Virol 2020; 30: e2103
2. Patel AB, Verma A. COVID-19 and Angiotensin-Converting En-zyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA 2020; doi: 10.1001/jama.2020.4812. Epub ahead of print 3. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020; 382: 1653-9
3. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. JAMA Cardiol 2020; doi: 10.1001/jamacardio.2020.1329. Epub ahead of print 5. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Version 2. Curr Hypertens Rep 2014; 16: 420
4. Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related dif-ference of ACE2 expression in rat lung. Life Sci 2006; 78: 2166-71
5. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogen-esis. J Pathol 2004; 203: 631-7
6. Zhang H, Baker A. Recombinant human ACE2: acing out angioten-sin II in ARDS therapy. Crit Care 2017; 21: 305
7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinker-nagel AS, et al. Endothelial cell infection and endotheliitis in CO-VID-19. Lancet 2020; 395: 1417-8
8. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothe-lium: diverse signals and effects. Hypertension 2005; 45: 163-9
9. Capelozzi VL, Allen TC, Beasley MB, Cagle PT, Guinee D, Hariri LP, et al. Molecular and Immune Biomarkers in Acute Respiratory Dis-tress Syndrome: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med 2017; 141: 1719-27
10. Xie-Zukauskas H, Das J, Short BL, Gutkind JS, Ray PE. Heparin in-hibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-depen-dent pathways. Vascul Pharmacol 2013; 58: 313-8
11. Koh KK, Sakuma I, Hayashi T, Kim SH, Chung WJ. Renin-angioten-sin system inhibitor and statins combination therapeutics - what have we learnt? Expert Opin Pharmacother 2015; 16: 949-53.